Human GCK adenoviral particles

The glucokinase (GCK) gene encodes a key enzyme involved in glucose metabolism and is primarily expressed in pancreatic β-cells and hepatocytes. As a key regulator of glucose homeostasis, GCK acts as a glucose sensor and catalyzes the phosphorylation of glucose to glucose-6-phosphate, the first step of glycolysis. In pancreatic β-cells, GCK activity directly affects insulin secretion in response to blood glucose levels, while in the liver, it mediates glucose uptake and glycogen synthesis. Mutations in the GCK gene are associated with maturity-onset diabetes of the young (MODY2), a disease characterized by mild hyperglycemia due to altered enzyme kinetics. Given its key role in glucose sensing and metabolic pathways, GCK is a promising therapeutic target in diabetes research. Studying the function and regulation of GCK often requires efficient gene delivery systems, such as adenoviral vectors, to achieve overexpression or knockdown in experimental models.

Human GCK adenoviral particles are genetically engineered recombinant adenoviruses designed to efficiently deliver the GCK gene to target cells. These particles exploit the natural infectious capacity of adenoviruses to broadly infect both dividing and non-dividing cells, ensuring stable transgene expression. Researchers use these particles to study the role of GCK in insulin secretion, hepatic glucose metabolism, and the pathogenesis of diabetes. In addition, they are also valuable tools for gene therapy research to help explore potential treatments for GCK-related diseases.